Evidence map›Paper›PMID 41039250›Full record

ArticleBMC neurology2025

Acetyl-DL-leucine (Tanganil™) in three patients with advanced multiple system atrophy.

Wolfgang H Oertel, Martin T Henrich, Elisabeth Sittig, Philipp T Meyer, Michael Strupp, Annette Janzen, Fanni F Geibl, Elisabeth Ruppert

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Wolfgang H Oertel *Department of Neurology, Philipps University of Marburg, Marburg, Germany. oertelw@med.uni-marburg.de.
Martin T Henrich *Department of Neurology, Philipps University of Marburg, Marburg, Germany.
Elisabeth SittigDepartment of Neurology, Philipps University of Marburg, Marburg, Germany.
Philipp T MeyerDepartment of Nuclear Medicine, Faculty of Medicine, Medical Center - University of Freiburg, University of Freiburg, Freiburg, Germany.
Michael StruppDepartment of Neurology, LMU University Hospital, LMU Munich, Munich, Germany.
Annette JanzenDepartment of Neurology, Philipps University of Marburg, Marburg, Germany.
Fanni F Geibl *Department of Neurology, Philipps University of Marburg, Marburg, Germany.
Elisabeth Ruppert *Department of Neurology, Philipps University of Marburg, Marburg, Germany. eruppert@unistra.fr.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMultiple system atrophy (MSA) is a rare, rapidly progressive alpha-synucleinopathy characterized by autonomic dysfunction, parkinsonism and marked cerebellar ataxia, with very limited treatment options. N-acetyl-DL-leucine (ADLL) (Tanganil™), a racemic derivative of leucine is usually well tolerated and has shown promise in improving cerebellar symptoms and reducing REM sleep behavior disorder (RBD), a common non-motor dream-sleep disorder feature of alpha-synucleinopathy. Given this dual potential, we treated three patients with advanced-stage MSA under compassionate use rules. CASE PRESENTATIONS: Three patients with advanced-stage MSA and severe cerebellar symptoms-two of whom also had moderate RBD-were treated with ADLL (Tanganil

conclusionsWhile ADLL improved RBD, it was poorly tolerated in these three patients with advanced-stage MSA of predominantly cerebellar type. Further studies are needed to evaluate its safety and efficacy in different, preferably early, stages of MSA.

Indexed as

LeucineMultiple System AtrophyHumansacetylleucineLeucineAdverse effectsAtaxiaCase reportMSA-CN-acetyl-DL-leucineNeurodegenerationREM sleep behavior disorder

Identifiers

PMID41039250
PMCPMC12490026

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.